Cempra Inc.


Roth Capital Reiterats Bullish Stance On Cempra Inc Following FDA Fast-Track Status For Solithromycin

In a research report published Wednesday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on shares of Cempra Inc (NASDAQ:CEMP) with a price …

Wednesday Morning Insights: Canadian Solar Inc. (CSIQ), Biocept Inc (BIOC), Barrick Gold Corporation (USA) (ABX), Cempra Inc (CEMP)

Canadian Solar Inc. (NASDAQ:CSIQ) plummeted nearly -11% in pre-market trading down to $21.

Stock Update (NASDAQ:CEMP): FDA Grants Fast Track Designation to Cempra, Inc. for Solithromycin in the Treatment of Community Acquired Bacterial Pneumonia

Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today …

Needham Raises Price Target for Cempra Inc (CEMP) Following 2Q15 Update

In a research report released Thursday, Needham analyst Alan Carr reiterated a Buy rating on Cempra Inc (NASDAQ:CEMP) and raised the price target …

Cempra Inc (CEMP) Reports Second Quarter 2015 Financial Results and Provides Corporate Update

Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today …

Roth Capital Reiterates Buy on Cempra Inc Ahead of 2Q15 Update

With Cempra Inc (NASDAQ:CEMP) preparing to release second-quarter earnings tomorrow after market close, Roth Capital analyst Debjit Chattopadhyay weighed in today with a …

Canaccord Maintains Buy on CalAmp Corp. Following Solid Q1:F’16 Results

In a research report released Wednesday, Canaccord analyst Michael Walkley maintained a Buy rating on CalAmp Corp. (NASDAQ:CAMP) with a price target of $26, …

Needham Maintains Buy On Cempra Inc Following 4Q14 Results; Remains Positive On Solithromycin Outlook

In a research report released today, Needham analyst Alan Carr maintained a Buy rating on Cempra (NASDAQ:CEMP) with a $42 price target, based on …

We See Significant Upside For Cempra Investors, Says Roth Capital

Roth Capital healthcare analyst Ed Arce is out today with some bullish thoughts on Cempra (NASDAQ:CEMP), initiating shares with a Buy rating and a $35 price …

Needham Lifts Cempra Price Target As Solithromycin Phase 3 Trial Meets Primary Endpoint

Needham analyst Alan Carr weighed in today on shares of Cempra (NASDAQ:CEMP) maintaining a Buy rating and raising the price target to $42 (from $28), as the company announced positive …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts